Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities

Journal of Internal Medicine - Tập 266 Số 1 - Trang 114-125 - 2009
Andreas Machens1, Kerstin Lorenz1, Henning Dralle1
1From the Department of General, Visceral and Vascular Surgery, Martin‐Luther‐University Halle‐Wittenberg, Halle/Saale, Germany

Tóm tắt

Abstract.The ground‐breaking discovery of genotype–phenotype relationships in hereditary medullary thyroid cancer has greatly facilitated early prophylactic thyroidectomy. Its timing depends not solely on a positive gene test but, more importantly, on the type of the REarranged during Transfection (RET) mutation and its underlying mode of RET receptor tyrosine kinase activation. In the past decade, the therapeutic corridor opened by molecular information has been defined down to a remarkable level of detail. Based on mutational risk profiles, preemptive thyroidectomy is recommended at 6 months of age for carriers of highest‐risk mutations, before the age of 5 years for carriers of high‐risk mutations, and before the age of 5 or 10 years for carriers of least‐high‐risk mutations. Additional lymph node dissection may not be needed in the absence of increased preoperative basal calcitonin levels. Better comprehension of RET function should enable the design of targeted therapies for RET carriers beyond surgical cure in whom the DNA‐based ‘window of opportunity’ has been missed.

Từ khóa


Tài liệu tham khảo

10.1634/theoncologist.8-6-531

10.1056/NEJM199609263351307

10.1210/jc.86.8.3948

10.1210/er.2006-0017

10.1530/EJE-07-0817

10.1038/sj.onc.1209698

10.1210/jc.2005-0064

10.1210/jc.83.2.487

Ito S, 1997, Biological properties of RET with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung’s disease phenotype, Cancer Res, 57, 2870

10.1038/sj.onc.1202742

10.1126/science.7824936

10.1006/bbrc.1996.0107

10.1089/thy.2007.0365

10.1210/jc.2003-030997

10.1111/j.1365-2265.2006.02509.x

10.1111/j.1365-2265.2008.03197.x

10.1089/thy.2006.16.609

10.1006/bbrc.1999.0237

10.1038/sj.onc.1201199

10.1158/0008-5472.CAN-04-2363

Iwashita T, 1996, Identification of tyrosine residues that are essential for transforming activity of the ret proto‐oncogene with MEN2A or MEN2B mutation, Oncogene, 12, 481

10.1111/j.1365-2265.2007.03056.x

10.1677/ERC-08-0096

10.1038/sj.onc.1203648

10.1073/pnas.94.7.3330

Kawai K, 2000, Tissue‐specific carcinogenesis in transgenic mice expressing the RET proto‐oncogene with a multiple endocrine neoplasia type 2A mutation, Cancer Res, 60, 5254

10.1093/emboj/19.4.612

10.1073/pnas.68.4.820

10.1210/jc.2005-2030

10.1677/joe.0.1700661

10.1053/jpsu.2002.32906

10.1056/NEJMoa012915

10.1056/NEJMoa043999

10.1016/j.surg.2004.04.034

10.1016/j.surg.2005.07.034

10.1016/j.jpedsurg.2006.09.019

10.1067/S0039-6060(03)00157-0

10.1111/j.1365-2265.2007.02964.x

10.1002/(SICI)1097-0142(19970801)80:3 <557::AID-CNCR5>3.0.CO;2-6

10.1067/msy.2000.11/6/111080

10.1016/j.jpedsurg.2007.05.015

10.1530/EJE-08-0476

Zakrzewska A, 2004, Late onset of medullary thyroid carcinoma with bilateral adrenal pheochromocytomas in the case of patient with MEN2, Pol Merkuriusz Lek, 17, 633

10.1111/j.1651-2227.2004.tb00854.x

10.1016/j.surg.2007.09.013

10.1016/j.surg.2005.01.014

10.1159/000185474

10.1007/s00268-002-6487-1

Scacheri PC, 2004, V804M RET mutation in MEN 2A: first report, J Intern Med, 255, 712

10.1210/jc.2004-0041

10.1530/eje.0.1440037

10.1067/msy.2002.121093

10.1530/eje.0.1390410

10.1089/thy.2006.0198

10.1067/msy.2002.123006

10.1210/jc.2004-1622

10.1111/j.1365-2796.1995.tb01208.x

10.1001/jama.1996.03540190047028

10.1210/jc.81.5.1780

10.1210/jc.83.3.770

10.1111/j.1365-2265.2007.02830.x

10.1007/s00268-006-0769-y

10.1111/j.1399-0004.2004.00312.x

10.1111/j.1365-2265.2007.03153.x

10.1210/jcem.86.8.7767

10.1210/jc.2007-1005

10.1080/07357900701518735

10.1677/joe.1.05838

10.1089/thy.2005.15.140

Grosfeld FJM, 1996, Psychosocial consequences of DNA analysis for MEN type 2, Oncology, 10, 141

10.1111/j.1365-2265.2008.03215.x

10.1007/BF03347478

10.1007/s00464-005-0642-3

10.1210/jcem.86.12.8070

10.1007/s00268-001-0020-9

10.1530/eje.1.02216

10.1002/(SICI)1097-0142(20000415)88:8<1909::AID-CNCR21>3.0.CO;2-A

10.1067/msy.2001.118380a

10.1210/jc.2002-021713

10.1067/msy.2003.61

10.1016/j.surg.2004.07.018

10.1067/msy.2001.108699

10.1002/cncr.10205

10.1016/S0022-3476(96)70084-7

10.1056/NEJMra044389

10.1210/jc.2007-1714

10.1038/sj.onc.1207810

10.1158/0008-5472.CAN-06-4605

10.1001/archsurg.142.3.289

Thông tin
Thông tin xuất bản

Journal of Internal Medicine

Tập 266 Số 1

114-125

Thông tin tác giả